Curvebeam Ai Ltd. · ASX:CVB
Curvebeam Ai — Shareholder Meeting (November 2023)
7 slides from Curvebeam Ai's shareholder meeting presentation, Nov 22, 2023
Slide 1: CurveBeam AI AGM
CURVEBEAM AI AGM November 2023
Slide 2: Disclaimer
DISCLAIMER Introduction are intended to identify future earnings, financial position and performance of CurveBeam. You are cautioned not to This presentation has been prepared by CurveBeam AI Limited (ACN 140 706 618) (CurveBeam or the Company) place undue reliance on these statements. These forward
Slide 3: FY23 CurveBeam AI Highlights
FY23 CURVEBEAM AI HIGHLIGHTS • StraxCorp and CurveBeam merger completed in Q1 FY23 • Pre-IPO round closed Q3 FY23 – raised $25m • The pre-IPO round showed a number of new institutional investors join our register. • Listed on ASX - raised A$25m in August 2023 – (ASX: CVB) • FY23 proforma revenue A$1
Slide 4: Stryker Foot & Ankle Update
STRYKER FOOT & ANKLE UPDATE STRYKER CORPORATION - FOOT & ANKLE DIVISION • Training for Stryker F&A occurred in late January 2023 • Stryker approved CurveBeam AI Limited as an approved supplier in May and made available financing options in June/July 2023 • AOFAS Conference – 20th to 23rd September 2
Slide 5: Enhanced HiRise Project
ENHANCED HIRISE™ PROJECT STRYKER CORPORATION - FOOT & ANKLE DIVISION • CurveBeam AI is developing enhancements to the HiRise™ platform, including a stronger X-Ray source for larger patients • This will enable higher resolution scans of the hip & knee required for surgical systems & patient specific
Slide 6: BMD HiRise Module Progress
BMD HIRISE™ MODULE PROGRESS • Target of the BMD module is to build a recurring high margin revenue • The new enhanced HiRise™ is needed to deploy a BMD product (post FDA) STRAXCORP – KEY POINTS • Company has identified & started discussions with several US sites for enrolling/collecting patients dat
Slide 7: In Closing
IN CLOSING • Deploying IPO capital to support HiRise™ placements for the rest of FY24 • The company focus remains 1. Driving growth in HiRise™ placements – especially in the US 2. Enhanced HiRise™ platform, especially for PSI & BMD functionality 3. Target launch for BMD SaaS business by the end of F